Skip to main content
Premium Trial:

Request an Annual Quote

Argos Soditic Acquires Cisbio Bioassays

NEW YORK (GenomeWeb News) – Private equity group Argos Soditic and management members of Cisbio Bioassays today announced that they have acquired Cisbio Bioassays from IBA for an undisclosed amount.

As a result, Cisbio will operate as an independent company.

Based in Codolet, France, Cisbio provides assays and reagents to researchers in the pharmaceutical, biotechnology, and academic markets, as well as to contract research organizations. Its technology portfolio includes Homogeneous Time Resolved Fluorescence. The company has facilities in Bedford, Mass., and Shanghai, and has 200 employees.

Cisbio said that it generates annual revenues of about €35 million ($47.4 million).

The deal will open up opportunities "for strategic growth and will enable [Cisbio] to strengthen its market positions," the firms said, adding that Argos Soditic will help Cisbio implement its strategic plan of innovation, new product launches, and international development.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.